CELC Stock Analysis: Celcuity | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.264m USD | 12M Return: 767.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 120M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 8.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, developing targeted therapies for solid tumors in the United States. Its lead candidate, Gedatolisib, is a pan-PI3K/mTOR inhibitor licensed from Pfizer that targets multiple isoforms of PI3K and the mTORC1/mTORC2 complexes. The drug is being developed for hormone receptor positive (HR+), HER2-negative advanced or metastatic breast cancer, as well as metastatic castration-resistant prostate cancer (mCRPC). The company was founded in 2011 and went public in September 2017.
As a clinical-stage biotech, Celcuity has no approved products on the market and relies on capital markets, partnerships, and licensing arrangements to fund its research and development pipeline. The PI3K/mTOR pathway is a well-established target in oncology drug development, and HR+/HER2- breast cancer represents the largest subtype of breast cancer cases, making it a commercially significant indication for targeted therapies.
- VIKTORIA-1 Phase 3 breast cancer data readout approaches
- Gedatolisib NDA submission advances toward FDA approval decision
- Rising R&D burn rate drives potential dilutive equity offering
| Net Income: -192.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.42 > 0.02 and ΔFCF/TA 4.82 > 1.0 |
| NWC/Revenue: 244k% < 20% (prev 152k%; Δ 91.8k% < -1%) |
| CFO/TA -0.42 > 3% & CFO -172.5m > Net Income -192.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (54.5m) vs 12m ago 26.50% < -2% |
| Gross Margin: -8.44% > 18% (prev -13.22%; Δ 4.78% > 0.5%) |
| Asset Turnover: 0.05% > 50% (prev 0.06%; Δ -0.01% > 0%) |
| Interest Coverage Ratio: -5.27 > 6 (EBIT TTM -172.8m / Interest Expense TTM 32.8m) |
| A: 0.92 (Total Current Assets 408.9m - Total Current Liabilities 33.2m) / Total Assets 410.2m |
| B: -1.22 (Retained Earnings -501.7m / Total Assets 410.2m) |
| C: -0.55 (EBIT TTM -172.8m / Avg Total Assets 314.1m) |
| D: 0.15 (Book Value of Equity 53.5m / Total Liabilities 356.6m) |
| Altman-Z'' = -1.52 = D |
As of July 08, 2026, the stock is trading at USD 115.72 with a total of 1,436,555 shares traded. Over the past week, the price has changed by +12.88%, over one month by +32.36%, over three months by +0.14% and over the past year by +767.47%.
Current recommended Stop Loss: 103.00 (which is 11% or 2 ATR below the current price).
Celcuity has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy CELC.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 160.6 | 38.8% |
P/B = 98.3526
Revenue TTM = 154k USD
EBIT TTM = -172.8m USD
EBITDA TTM = -172.7m USD
Long Term Debt = 323.4m USD (from longTermDebt, last quarter)
Short Term Debt = 13.0k USD (from shortTermDebt, last quarter)
Debt = 323.5m USD (corrected: LT Debt 323.4m + ST Debt 13.0k) + Leases 13.0k
Net Debt = 178.3m USD (calculated: Debt 323.5m - CCE 145.2m)
Enterprise Value = 5.44b USD (5.26b + Debt 323.5m - CCE 145.2m)
Interest Coverage Ratio = -5.27 (Ebit TTM -172.8m / Interest Expense TTM 32.8m)
EV/FCF = -31.47x (Enterprise Value 5.44b / FCF TTM -172.9m)
FCF Yield = -3.18% (FCF TTM -172.9m / Enterprise Value 5.44b)
FCF Margin = -112k% (FCF TTM -172.9m / Revenue TTM 154k)
Net Margin = -125k% (Net Income TTM -192.9m / Revenue TTM 154k)
Gross Margin = -8.44% ((Revenue TTM 154k - Cost of Revenue TTM 167k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 13.27 (Enterprise Value 5.44b / Total Assets 410.2m)
Interest Expense / Debt = 10.15% (Interest Expense 32.8m / Debt 323.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -136.5m (EBIT -172.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.31 (Total Current Assets 408.9m / Total Current Liabilities 33.2m)
Debt / Equity = 6.04 (Debt 323.5m / totalStockholderEquity, last quarter 53.5m)
Debt / EBITDA = -1.03 (negative EBITDA) (Net Debt 178.3m / EBITDA -172.7m)
Debt / FCF = -1.03 (negative FCF - burning cash) (Net Debt 178.3m / FCF TTM -172.9m)
Total Stockholder Equity = 78.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -61.40% (Net Income -192.9m / Total Assets 410.2m)
RoE = -244.6% (Net Income TTM -192.9m / Total Stockholder Equity 78.9m)
RoCE = -42.96% (EBIT -172.8m / Capital Employed (Equity 78.9m + L.T.Debt 323.4m))
RoIC = -36.22% (negative operating profit) (NOPAT -136.5m / Invested Capital 377.0m)
WACC = 8.62% (E(5.26b)/V(5.59b) * Re(8.66%) + D(323.5m)/V(5.59b) * Rd(10.15%) * (1-Tc(0.21)))
Discount Rate = 8.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 32.53%
[DCF] Fair Price = unknown (Cash Flow -172.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.65 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.98 | Chg30d=+2.97% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-1.08 | Chg30d=-6.37% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=-3.53 | Chg30d=+6.61% | Revisions=-25% | GrowthEPS=-9.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=0.74 | Chg30d=+167.27% | Revisions=-25% | GrowthEPS=+121.0% | GrowthRev=+810.1%
[Analyst] Revisions Ratio: -50% (up=0, down=3)